​

Funding Round

Series B - Autobahn Therapeutics

Series B - Autobahn Therapeutics

Investment Firm

Overview

Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.

Announced Date

Jun 11, 2020

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

ARCH Venture Partners

ARCH Venture Partners

ARCH Venture Partners is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

8

Investor Name
Participant InvestorBristol-Myers Squibb
Participant InvestorBiogen
Participant InvestorInvus
Participant InvestorSection 32
Participant InvestorARCH Venture Partners

Round Details and Background

Autobahn Therapeutics raised $76000000 on 2020-06-11 in Series B

Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 11, 2020
Series B - Autobahn Therapeutics
10-76.0M
Sep 08, 2022
Venture Round - Autobahn Therapeutics
11-32.7M
Jul 24, 2024
Series C - Autobahn Therapeutics
15-100.0M

Recent Activity

There is no recent news or activity for this profile.